Essentra’s (ESNT) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank restated their buy rating on shares of Essentra (LON:ESNT) in a research note published on Thursday morning, Marketbeat reports. The firm currently has a GBX 160 target price on the stock.

Several other research analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Essentra from GBX 165 to GBX 150 and set a “buy” rating on the stock in a research note on Thursday, January 15th. Royal Bank Of Canada reduced their target price on shares of Essentra to GBX 130 and set an “outperform” rating on the stock in a report on Wednesday. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of GBX 164.

Essentra Price Performance

Shares of Essentra stock opened at GBX 91.70 on Thursday. The firm has a market capitalization of £261.18 million, a PE ratio of 27.79, a price-to-earnings-growth ratio of 3.84 and a beta of 0.86. The company has a current ratio of 2.20, a quick ratio of 0.50 and a debt-to-equity ratio of 47.67. Essentra has a 12 month low of GBX 88.53 and a 12 month high of GBX 123.80. The business’s 50-day moving average price is GBX 101.65 and its 200-day moving average price is GBX 100.59.

Essentra (LON:ESNT) last released its earnings results on Tuesday, March 17th. The company reported GBX 6.10 earnings per share for the quarter. Essentra had a return on equity of 0.79% and a net margin of 0.70%. Sell-side analysts forecast that Essentra will post 524.137931 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Kath Durrant purchased 10,894 shares of Essentra stock in a transaction that occurred on Tuesday, March 17th. The shares were acquired at an average cost of GBX 91 per share, for a total transaction of £9,913.54. Also, insider Rowan Baker purchased 10,977 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was bought at an average cost of GBX 91 per share, for a total transaction of £9,989.07. Insiders have purchased a total of 61,871 shares of company stock worth $5,710,261 in the last ninety days. 0.48% of the stock is owned by insiders.

Trending Headlines about Essentra

Here are the key news stories impacting Essentra this week:

• Positive Sentiment: Significant insider buying from senior executives (Steve Good ~40,000 shares; Kath Durrant and Rowan Baker ~10.9k each near GBX 91) signals management confidence and can help underpin the share price. Insider Trades Alert
• Positive Sentiment: Berenberg Bank reaffirmed a “buy” rating with a GBX 160 target, supporting upside relative to current levels. Broker Ratings (Digital Look)
• Positive Sentiment: Jefferies re‑affirmed a “buy” rating on Essentra, adding another broker vote of confidence for investors watching recovery execution. Broker Ratings (Digital Look)
• Neutral Sentiment: Q3 results broadly met expectations (GBX 6.10 EPS) but showed margin pressure and weak return metrics — this limits downside from an earnings miss but means upside depends on margin recovery. Earnings Coverage
• Negative Sentiment: Royal Bank of Canada cut its price target to GBX 130 (while keeping an “outperform”), and Deutsche Bank also trimmed its target — these downward revisions can pressure near-term sentiment despite buy ratings. RBC Price Target Cut

About Essentra

Essentra plc is a leading global provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded and metal items.

Headquartered in the United Kingdom, Essentra’s global network extends to 28 countries worldwide and includes c.3,000 employees, 14 manufacturing facilities, 26 distribution centres and 37 sales & service centres serving c.64,000 customers with a rapid supply of low cost but essential products for a variety of applications in industries such as equipment manufacturing, automotive, fabrication, electronics, medical and renewable energy.